XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) - USD ($)
3 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]    
Revenue $ 1,111,797 $ 872,287 [1]
Cost of revenue (exclusive of amortization shown separately below) (593,506) (525,486) [2]
Gross profit 518,291 346,801
Other income    
Government support income 193,267 126,128 [2]
Operating expenses    
Selling, general and administrative expenses (2,659,824) (1,949,016) [2]
Development and regulatory approval expenses (486,169) (948,752) [2]
Depreciation and amortization (303,378) (300,422) [2]
Impairment of long-lived assets (261,780) [2]
Total operating expenses (3,711,151) (3,198,190)
Loss from operations (2,999,593) (2,725,261)
Other income (expense), net    
Interest expense (3,903) (22,327)
Realized foreign exchange loss (51)
Interest income 8,504 52,840
Total other income, net 4,601 [3] 30,462 [2],[4]
Net loss (2,994,992) (2,694,799) [1]
Net loss attributable to non-controlling interest (11,986) (9,166)
Net loss attributable to Intelligent Bio Solutions Inc. (2,983,006) (2,685,633)
Other comprehensive income (loss)    
Foreign currency translation gain 48,716 216,355
Total other comprehensive income 48,716 216,355
Comprehensive loss (2,946,276) (2,478,444)
Comprehensive loss attributable to non-controlling interest (11,986) (9,166)
Comprehensive loss attributable to Intelligent Bio Solutions Inc. $ (2,934,290) $ (2,469,278)
Net loss per share, basic $ (0.35) $ (0.70)
Net loss per share, diluted $ (0.35) $ (0.70)
Weighted average shares outstanding, basic 8,546,934 3,811,090
Weighted average shares outstanding, diluted 8,546,934 3,811,090
[1] Comparative amounts for the prior period have been reclassified to conform to current period presentations.
[2] Comparative amounts for the prior period have been reclassified to conform to current period presentations.
[3] Other segment items included interest income, interest expense and realized currency loss.
[4] Other segment items included interest income, interest expense and realized currency loss.